IMMP Soars 1,646% While IOVA and PXS Jump on EPS Revisions
Immutep Limited ADR (IMMP) skyrocketed 1,646.2% to $4.54 after our EPS revision screener flagged a 25.5% next-year growth estimate on September 27. Iovance Biotherapeutics (IOVA) climbed 31.8% to $14.23 following a raised FY2026 revenue outlook and a 52.0% EPS growth estimate, while Pyxis Tankers (PXS) gained 18.2% to $7.61 on a 39.0% EPS revision. Lumentum (LITE) and Uxin (UXIN) also posted double-digit gains, reinforcing that upward earnings revisions are driving sharp price appreciation across sectors.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| IMMP | Healthcare | 2026-09-27 | N/A | +1646.2% |
| IOVA | Healthcare | 2026-09-24 | N/A | +31.8% |
| PXS | Energy | 2026-09-29 | N/A | +18.2% |
| LITE | Technology | 2026-09-28 | N/A | +13.5% |
| UXIN | Consumer Cyclical | 2026-09-29 | N/A | +11.4% |
Why did IMMP stock jump in October 2026?
IMMP jumped 1,646.2% (from $0.26 to $4.54) after analysts raised its next-year EPS growth estimate to 25.5% on September 27.
The stock was detected by our EPS revision screener at $0.26, and the subsequent rally reflects growing optimism around the company's pipeline, though no earnings-related news was found in the window. Immutep, a healthcare firm focused on immuno-oncology, likely benefited from sector-wide momentum and increased investor interest in small-cap biotechs with improving earnings prospects. The magnitude of the move suggests a short squeeze or speculative buying, but the EPS revision remains the core catalyst.
IMMP EPS revision history → · Screener snapshot from 2026-09-27 →
FAQ: IMMP
Why did IMMP stock jump?
IMMP jumped 1,646.2% from $0.26 to $4.54 after its next-year EPS growth estimate was revised to 25.5% on September 27, 2026.
Is IMMP a buy after the rally?
With a 25.5% EPS growth estimate and no recent earnings news, IMMP's valuation is highly speculative; investors should consider the risk of a pullback after such a massive gain.
What is IMMP's EPS growth estimate?
IMMP's current EPS growth estimate for next year is 25.5%, as per the latest analyst revisions.
Why did IOVA stock jump in October 2026?
IOVA jumped 31.8% (from $10.80 to $14.23) after analysts raised its next-year EPS growth estimate to 52.0% on September 24.
The stock surged to over two-year highs on September 29 after the company raised its FY2026 revenue outlook to $410–$420 million, up from $350–$370 million, citing strong demand for Amtagvi and Proleukin. The revised midpoint of $415 million exceeds consensus of $402.8 million, implying nearly 60% annual growth. Our screener detected the EPS revision early, and the guidance hike confirmed the bullish thesis, driving the stock higher.
IOVA EPS revision history → · Screener snapshot from 2026-09-24 →
FAQ: IOVA
Why did IOVA stock surge?
IOVA surged 31.8% to $14.23 after raising its FY2026 revenue guidance to $410–$420 million and reporting a 52.0% next-year EPS growth estimate.
Is IOVA a buy after the rally?
IOVA's raised guidance and 52.0% EPS growth estimate suggest strong momentum, but the stock's 31.8% jump may warrant caution; analysts will watch Q3 results in November.
What caused IOVA's guidance raise?
IOVA raised its FY2026 revenue outlook due to record Q2 product revenue of $99.3 million, driven by Amtagvi and Proleukin demand, and an expanding treatment center network.
Why did PXS stock jump in October 2026?
PXS jumped 18.2% (from $6.44 to $7.61) after analysts raised its next-year EPS growth estimate to 39.0% on September 29.
The energy sector has been volatile, but Pyxis Tankers' improved earnings outlook likely attracted value investors seeking exposure to shipping. No earnings-related news was found in the window, so the move appears driven by the EPS revision and broader sector trends. Our screener caught the revision early, and the price gain confirms market recognition.
PXS EPS revision history → · Screener snapshot from 2026-09-29 →
FAQ: PXS
Why did PXS stock jump?
PXS jumped 18.2% from $6.44 to $7.61 after its next-year EPS growth estimate was revised to 39.0% on September 29, 2026.
Is PXS a buy after the rally?
PXS's 39.0% EPS growth estimate is attractive, but without recent news, the rally may be speculative; monitor energy shipping rates for confirmation.
What is PXS's EPS growth estimate?
PXS's current EPS growth estimate for next year is 39.0%, according to the latest analyst revisions.
Why did LITE stock jump in October 2026?
LITE jumped 13.5% (from $921.32 to $1045.78) after analysts raised its next-year EPS growth estimate to 57.6% on September 28.
The technology sector, particularly optical components, has benefited from AI-driven demand, and Lumentum's strong earnings outlook positions it well. Although no specific earnings news was found, the stock was mentioned in a Wall Street analyst roundup on September 30, which may have brought attention to its revised estimates. Our screener detected the revision before the price surge, highlighting the predictive power of EPS trends.
LITE EPS revision history → · Screener snapshot from 2026-09-28 →
FAQ: LITE
Why did LITE stock jump?
LITE jumped 13.5% from $921.32 to $1045.78 after its next-year EPS growth estimate was revised to 57.6% on September 28, 2026.
Is LITE a buy after the rally?
LITE's 57.6% EPS growth estimate is strong, and with AI demand boosting optical components, the stock may continue to benefit, but valuation should be considered after the 13.5% gain.
What is LITE's EPS growth estimate?
LITE's current EPS growth estimate for next year is 57.6%, based on recent analyst revisions.
Why did UXIN stock jump in October 2026?
UXIN jumped 11.4% (from $1.23 to $1.37) after analysts raised its next-year EPS growth estimate to 28.6% on September 29.
The consumer cyclical sector has faced headwinds, but Uxin's improved earnings outlook suggests a potential turnaround in the used car market. No earnings-related news was found in the window, so the move is likely driven by the EPS revision and speculative interest. Our screener detected the revision early, and the subsequent price gain indicates growing investor confidence.
UXIN EPS revision history → · Screener snapshot from 2026-09-29 →
FAQ: UXIN
Why did UXIN stock jump?
UXIN jumped 11.4% from $1.23 to $1.37 after its next-year EPS growth estimate was revised to 28.6% on September 29, 2026.
Is UXIN a buy after the rally?
UXIN's 28.6% EPS growth estimate is promising, but the stock remains highly speculative; consider the lack of recent news and China's economic conditions.
What is UXIN's EPS growth estimate?
UXIN's current EPS growth estimate for next year is 28.6%, according to the latest analyst revisions.
Today's top performers highlight the outsize impact of upward EPS revisions, particularly in small-cap healthcare and energy names, where early detection can lead to substantial gains. The market is rewarding companies with improving earnings prospects, even in the absence of immediate news, signaling a bullish sentiment for stocks with strong growth estimates.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →